These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 332054)

  • 1. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
    Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA; Blacker C
    Ann Endocrinol (Paris); 1977; 38(4):291-301. PubMed ID: 332054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutical effects of bromocriptine in 10 acromegalic patients: study of somatotrophic function and glucose tolerance test (author's transl)(proceedings)].
    Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA
    Ann Endocrinol (Paris); 1976; 37(4):299-300. PubMed ID: 1037360
    [No Abstract]   [Full Text] [Related]  

  • 3. Sleep-related growth hormone release following 2-bromo-alpha-ergocriptine treatment in acromegalic patients.
    Chihara K; Kato Y; Abe H; Furumoto M; Maeda K
    J Clin Endocrinol Metab; 1977 Jan; 44(1):78-84. PubMed ID: 576232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of acromegaly using bromocriptine].
    Köbberling J; Schwinn G; Dirks H
    Dtsch Med Wochenschr; 1975 Jul; 100(29):1540-2. PubMed ID: 1149634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size.
    Oppizzi G; Liuzzi A; Chiodini P; Dallabonzana D; Spelta B; Silvestrini F; Borghi G; Tonon C
    J Clin Endocrinol Metab; 1984 Jun; 58(6):988-92. PubMed ID: 6725515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bromocriptine therapy in acromegaly (author's transl)(proceedings)].
    Schaison G; Mowszowicz I
    Ann Endocrinol (Paris); 1976; 37(4):297-8. PubMed ID: 1037359
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
    Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
    Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine treatment of acromegaly.
    Cassar J; Mashiter K; Joplin GF
    Metabolism; 1977 May; 26(5):539-46. PubMed ID: 576725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine therapy in acromegaly. A long-term review of 35 cases.
    Sachdev Y; Gopal K; Garg VK
    Postgrad Med J; 1981 Apr; 57(666):210-6. PubMed ID: 7027229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
    Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
    J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of CB 154 in the treatment of acromegaly in France (author's transl)(proceedings)].
    Bricaire H
    Ann Endocrinol (Paris); 1976; 37(4):305-8. PubMed ID: 1037363
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolic and clinical studies on patients with acromegaly treated with bromocriptine over 22 months.
    Schwinn G; Dirks H; McIntosh C; Köbberling J
    Eur J Clin Invest; 1977 Apr; 7(2):101-7. PubMed ID: 404154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
    Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
    J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine does not alter growth hormone (GH) responsiveness to GH-releasing hormone in acromegaly.
    Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Liuzzi A; Chiodini PG
    J Clin Endocrinol Metab; 1986 Mar; 62(3):601-4. PubMed ID: 3080469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No effect of treatment with sodium valproate on plasma growth hormone in bromocriptine unresponsive acromegaly.
    Nortier JW; Croughs RJ; Schwarz F; Thijssen JH
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):162-4. PubMed ID: 3082095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients.
    Chiodini PG; Liuzzi A; Muller EE; Botalla L; Cremascoli G; Oppizzi G; Verde G; Silvestrini F
    J Clin Endocrinol Metab; 1976 Aug; 43(2):356-63. PubMed ID: 950367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different dopaminergic agents in the treatment of acromegaly.
    Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
    J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.
    Demura R; Yamaguchi H; Demura H; Shizume K
    Endocrinol Jpn; 1978 Aug; 25(4):355-9. PubMed ID: 710371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.